TAVANTA THERAPEUTICS

Serial Number 88916837
Registration 6521716
700

Registration Progress

Application Filed
May 14, 2020
Under Examination
Dec 8, 2020
Approved for Publication
Oct 13, 2020
Published for Opposition
Oct 13, 2020
Registered
Oct 12, 2021

Trademark Image

TAVANTA THERAPEUTICS

Basic Information

Serial Number
88916837
Registration Number
6521716
Filing Date
May 14, 2020
Registration Date
October 12, 2021
Published for Opposition
October 13, 2020
Drawing Code
4000

Status Summary

Current Status
Active
Status Code
700
Status Date
Oct 12, 2021
Registration
Registered
Classes
042

Rights Holder

TAVANTA THERAPEUTICS, INC.

03
Address
201 KING OF PRUSSIA ROAD
SUITE 650
RADNOR, PA 19087

Ownership History

Druggability Technologies Holdings, Ltd

Original Applicant
16
Dublin IE

Druggability Technologies Holdings, Ltd

Owner at Publication
16
Dublin IE

Druggability Technologies Holdings, Ltd

Original Registrant
16
Dublin IE

TAVANTA THERAPEUTICS, INC.

New Owner After Registration #1
03
RADNOR, PA

Legal Representation

Attorney
Thomas G. Peterson

USPTO Deadlines

Next Deadline
705 days remaining
Section 8 (6-Year) Declaration Due (Based on registration date 2021-10-12)
Due Date
October 12, 2027
Grace Period Ends
April 12, 2028
Additional deadlines exist. Contact your attorney for complete deadline information.

Application History

29 events
Date Code Type Description Documents
Jul 27, 2022 ASGN I AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP Loading...
Oct 12, 2021 R.PR A REGISTERED-PRINCIPAL REGISTER Loading...
Sep 9, 2021 SUNA E NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED Loading...
Sep 8, 2021 CNPR P ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED Loading...
Aug 3, 2021 ALIE A ASSIGNED TO LIE Loading...
Aug 3, 2021 CRFA I CORRESPONDENCE RECEIVED IN LAW OFFICE Loading...
Aug 3, 2021 TEME I TEAS/EMAIL CORRESPONDENCE ENTERED Loading...
Jul 30, 2021 TROA I TEAS RESPONSE TO OFFICE ACTION RECEIVED Loading...
Jul 21, 2021 CNRT W SU - NON-FINAL ACTION - WRITTEN Loading...
Jul 21, 2021 GNRT O NON-FINAL ACTION E-MAILED Loading...
Jul 21, 2021 GNRN O NOTIFICATION OF NON-FINAL ACTION E-MAILED Loading...
Jun 22, 2021 SUPC I STATEMENT OF USE PROCESSING COMPLETE Loading...
Jun 17, 2021 AITU A CASE ASSIGNED TO INTENT TO USE PARALEGAL Loading...
Jun 8, 2021 EISU I TEAS STATEMENT OF USE RECEIVED Loading...
Jun 8, 2021 IUAF S USE AMENDMENT FILED Loading...
Dec 8, 2020 NOAM E NOA E-MAILED - SOU REQUIRED FROM APPLICANT Loading...
Oct 13, 2020 PUBO A PUBLISHED FOR OPPOSITION Loading...
Oct 13, 2020 NPUB E OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED Loading...
Sep 23, 2020 NONP E NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED Loading...
Sep 10, 2020 CNSA P APPROVED FOR PUB - PRINCIPAL REGISTER Loading...
Sep 9, 2020 TEME I TEAS/EMAIL CORRESPONDENCE ENTERED Loading...
Sep 8, 2020 TROA I TEAS RESPONSE TO OFFICE ACTION RECEIVED Loading...
Sep 8, 2020 CRFA I CORRESPONDENCE RECEIVED IN LAW OFFICE Loading...
Aug 18, 2020 CNRT R NON-FINAL ACTION WRITTEN Loading...
Aug 18, 2020 GNRT F NON-FINAL ACTION E-MAILED Loading...
Aug 18, 2020 GNRN O NOTIFICATION OF NON-FINAL ACTION E-MAILED Loading...
Aug 12, 2020 DOCK D ASSIGNED TO EXAMINER Loading...
May 28, 2020 NWOS I NEW APPLICATION OFFICE SUPPLIED DATA ENTERED Loading...
May 18, 2020 NWAP I NEW APPLICATION ENTERED Loading...

Detailed Classifications

Class 042
Scientific, medical and pharmaceutical research and development, namely, development of new pharmaceutical formulations, development of pharmaceutical formulations for efficient drug release, development of clinical uses and treatments for new chemical entities and known pharmaceutical compounds; research and development of new pharmaceutical formulations; research and development of pharmaceutical formulations for efficient drug release; research and development of pharmaceuticals, namely, pharmaceuticals for treating cancer, multiple sclerosis, cystic fibrosis, tuberous sclerosis complex, and other disease states; research and development of new chemical entities and known pharmaceutical compounds; research and development of medicines, namely, for the treatment of cancer, multiple sclerosis, cystic fibrosis, tuberous sclerosis complex, and other disease states; scientific investigations for medical purposes; research and development of medicines, namely, new chemical entities and known pharmaceutical compounds
First Use Anywhere: Sep 1, 2020
First Use in Commerce: Sep 1, 2020

Classification

International Classes
042

Disclaimers

The following terms have been disclaimed and are not claimed as part of the trademark:
General Disclaimer
"THERAPEUTICS"